Education
About Us
Working with TipRanks
Follow Us
Anavex Life Sciences (AVXL)
:AVXL
AVXL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.93 - $14.44
Previous CloseN/A
Volume1.46M
Average Volume (3M)1.14M
Market Cap
$930.19M
Enterprise Value$614.16M
Total Cash (Recent Filing)$115.77M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.60
Next Earnings
Aug 12, 2025EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding85,416,695
10 Day Avg. Volume1,477,054
30 Day Avg. Volume1,143,146
Financial Highlights & Ratios
PEG Ratio0.83
Price to Book (P/B)3.94
Price to Sales (P/S)0.00
P/FCF Ratio-15.39
Enterprise Value/Market Cap0.66
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-12.56
Forecast
1Y Price Target
$28.50Price Target Upside161.71% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressThe successful completion of enrollment in the Phase 2 clinical study for ANAVEX3-71 signals progress in developing a treatment for schizophrenia.
Market OpportunityPossible blarcamesine EU market entry could make the European market opportunity highly lucrative.
Regulatory ApprovalPositive commentary from the European Medicines Agency could have a huge upside to the stock and indicate success with other ex-US regulatory bodies.
Bears Say
Regulatory RequirementsThe FDA will likely require the company to run a larger Phase 3 study prior to an NDA submission.
Regulatory UncertaintyThe uncertainty around approval in the U.S. and lack of any ex-US partnership news are the key holdups for the stock.
Anavex Life Sciences News
AVXL FAQ
What was Anavex Life Sciences’s price range in the past 12 months?
Anavex Life Sciences lowest stock price was $4.93 and its highest was $14.44 in the past 12 months.
What is Anavex Life Sciences’s market cap?
Anavex Life Sciences’s market cap is $930.19M.
When is Anavex Life Sciences’s upcoming earnings report date?
Anavex Life Sciences’s upcoming earnings report date is Aug 12, 2025 which is in 4 days.
How were Anavex Life Sciences’s earnings last quarter?
Anavex Life Sciences released its earnings results on May 13, 2025. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.15 by $0.02.
Is Anavex Life Sciences overvalued?
According to Wall Street analysts Anavex Life Sciences’s price is currently Undervalued.
Does Anavex Life Sciences pay dividends?
Anavex Life Sciences does not currently pay dividends.
What is Anavex Life Sciences’s EPS estimate?
Anavex Life Sciences’s EPS estimate is -0.14.
How many shares outstanding does Anavex Life Sciences have?
Anavex Life Sciences has 85,416,695 shares outstanding.
What happened to Anavex Life Sciences’s price movement after its last earnings report?
Anavex Life Sciences reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.15. Following the earnings report the stock price went down -5.029%.
Which hedge fund is a major shareholder of Anavex Life Sciences?
Currently, no hedge funds are holding shares in AVXL
Anavex Life Sciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$28.50 (161.71% Upside)
$28.50 (161.71% Upside)
Blogger Sentiment
Bullish
AVXL Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 4.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 0.7%
Last 30 Days ▼ 4.2%
Last 30 Days ▼ 4.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
60.96%
12-Months-Change
Fundamentals
Return on Equity
-40.13%
Trailing 12-Months
Asset Growth
-19.07%
Trailing 12-Months
Company Description
Anavex Life Sciences
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
AVXL Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in Alzheimer's and schizophrenia treatment development, supported by a strong financial position and strategic board appointments. However, the company continues to face challenges with net losses and regulatory uncertainties.View all AVXL earnings summariesAVXL Stock 12 Month Forecast
Average Price Target
$28.50
▲(161.71% Upside)
Technical Analysis
Vir Biotechnology
―
Nurix Therapeutics
―
AbCellera Biologics
―
Day One Biopharmaceuticals
―
Bicara Therapeutics Inc.
―
Ownership Overview
3.33% Insiders
8.50% Mutual Funds
0.23% Other Institutional Investors
74.28% Public Companies and
Individual Investors